Premier Alternatives

Octave Bioscience

Menlo Park, CA · Founded 2014 · Privately Held (backing)

Operator of a biomarker-driven precision medicine company intended to improve monitoring and treatment decisions for neurodegenerative diseases. Octave Bioscience is based in Menlo Park, CA and was founded in 2014. Its last reported valuation was $143 million in Jul 2023. It has raised $129 million across 5 recorded rounds; the latest was a $31.8 million early-stage round in Mar 2025.

Last reported valuation
$143.0M
Oct 2026
Priced at
—
Total raised
$129.2M
Last round
Early Stage VC
Mar 2025

Octave Bioscience key facts

as of Oct 2026
  • Operator of a biomarker-driven precision medicine company intended to improve monitoring and treatment decisions for neurodegenerative diseases.
  • Octave Bioscience is valued at approximately $143.0M as of Oct 2026 (last reported valuation).
  • It has raised $129.2M across 5 recorded rounds; the latest was Early Stage VC ($31.8M) in Mar 2025.
  • Notable investors include European Innovation Council, Kleiner Perkins, S32, Deerfield Management, Casdin Capital — 18 tracked in total.
  • Octave Bioscience has filed 5 Form Ds with the SEC since 2017, most recently Mar 2025 ($31.8M sold to 20 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$143.0M

Octave Bioscience's last reported valuation, Jul 2023. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Octave Bioscience with a free account
  • ·The complete investor list: 18 names
  • ·Watch Octave Bioscience: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Octave Bioscience funding rounds

5 rounds
Mar 2025Early Stage VC$31.8MSEC filing▮
Sep 2023Early Stage VC$7.0MSEC filing▮
Jan 2023Early Stage VC$32.5MSEC filing▮
Oct 2020Early Stage VC$32.0MSEC filing▮
Nov 2014Seed Round$2.5MSEC filing▮
Full funding history →

Octave Bioscience valuation

Octave Bioscience's last reported valuation was $143 million in Jul 2023. No priced round, secondary trade or fund mark has surfaced since.

How much has Octave Bioscience raised?

Octave Bioscience has raised $129 million across 5 recorded rounds since 2014. The largest was a $7 million early-stage round in Sep 2023; the most recent was a $31.8 million early-stage round in Mar 2025.

Octave Bioscience has filed 5 Form Ds with the SEC since 2017, most recently in Mar 2025 ($31.8 million sold to 20 investors).

Octave Bioscience investors

18 investors are on record for Octave Bioscience, including European Innovation Council, Kleiner Perkins, S32 and Deerfield Management. By type, the record holds 7 venture capital firms. The early-stage round in Mar 2025 drew 20 investors.

About Octave Bioscience

Operator of a biomarker-driven precision medicine company intended to improve monitoring and treatment decisions for neurodegenerative diseases. The company offers comprehensive biomarker testing and data analytics capabilities, enabling neurologists and patients managing Multiple Sclerosis and Parkinson's disease to gain objective insights that support informed care decisions and improved patient outcomes.

Sector
Healthcare
HQ
Menlo Park, CA, United States
Founded
2014
Employees
72
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.